Evidence map›Paper›PMID 36925179›Full record

ArticleThe Lancet. Global health2023

Effects of public financing of essential maternal and child health interventions across wealth quintiles in Nigeria: an extended cost-effectiveness analysis.

Wenhui Mao, David Watkins, Miriam L Sabin, Katy Huang, Etienne Langlois, Yewande Ogundeji, Helga Fogstad, Marco Schäferhoff, Gavin Yamey, Osondu Ogbuoji

Full text read
In one paragraph

Article in The Lancet. Global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenhui MaoCenter for Policy Impact in Global Health, Duke Global Health Institute, Durham, NC, USA.
David WatkinsSeattle, WA, USA.
Miriam L SabinThe Partnership for Maternal, Newborn and Child Health, WHO, Geneva, Switzerland.
Katy HuangThe Partnership for Maternal, Newborn and Child Health, WHO, Geneva, Switzerland.
Etienne LangloisThe Partnership for Maternal, Newborn and Child Health, WHO, Geneva, Switzerland.
Yewande OgundejiHealth Strategy and Delivery Foundation, Maitama, Abuja, Nigeria.
Helga FogstadThe Partnership for Maternal, Newborn and Child Health, WHO, Geneva, Switzerland.
Marco SchäferhoffOpen Consultants, Berlin, Germany.
Gavin YameyCenter for Policy Impact in Global Health, Duke Global Health Institute, Durham, NC, USA; Margolis Center for Health Policy, Duke University, Durham, NC, USA.
Osondu OgbuojiCenter for Policy Impact in Global Health, Duke Global Health Institute, Durham, NC, USA; Margolis Center for Health Policy, Duke University, Durham, NC, USA. Electronic address: osondu.ogbuoji@duke.edu.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundMaternal and newborn mortality rates in Nigeria are among the highest globally, and large socioeconomic inequalities exist in access to maternal, newborn, and child health (MNCH) services in the country. Inequalities also exist in catastrophic health expenditure among households in Nigeria. We aimed to estimate the health and financial risk protection benefits across different wealth groups in Nigeria if a policy of public financing of MNCH interventions were to be introduced.

methodsWe did an extended cost-effectiveness analysis to estimate the health and financial risk protection benefits, across different household wealth quintiles, of a public-financing policy that assumes zero out-of-pocket costs to patients at the point of care for 18 essential MNCH services. We projected health outcomes (deaths in children aged <5 years [under-5 deaths] and maternal deaths) and private expenditure averted using the Lives Saved Tool with data extracted from national surveys. We modelled three scenarios: 1) coverage expansion at a rate equal to the trend observed between 2013 and 2018 (status quo); 2) annual coverage expansion by 5% compared with the status quo (uniform scale-up scenario); and 3) annual coverage expansion by 10%, 8%, 6%, 4%, and 2% compared with the status quo from the poorest to the wealthiest quintiles, respectively (pro-poor scale-up scenario).

findingsOur analysis shows that, if an additional 5% increase in coverage was provided for all wealth quintiles between 2019 and 2030, this uniform scale-up policy would prevent more than 0·11 million maternal deaths and 1·05 million under-5 deaths, avert US$1·8 billion in private expenditure, and avert 3266 cases of catastrophic health expenditure. The incremental cost effectiveness ratio would be $44 per life-year gained, which is highly cost-effective when compared with the gross domestic product per capita of Nigeria for 2018 ($2028). The policy would prevent a higher number of under-5 deaths and catastrophic health expenditure cases in poorer quintiles, but would prevent more maternal deaths and private expenditure in wealthier quintiles. If poorer populations experienced a greater increase in service coverage (ie, the pro-poor scale-up scenario), more maternal and under-5 deaths would be prevented in the poorer quintiles and more private expenditure would be averted than would be under previous scenarios.

interpretationPublic financing of essential MNCH interventions in Nigeria would provide substantial health and financial risk protection benefits to Nigerian households. These benefits would accrue preferentially to the poorest quintiles and would contribute towards reduction of health and socioeconomic inequalities in Nigeria. The distribution would be more pro-poor if public financing of MNCH interventions could target poor households.

fundingWHO Partnership for Maternal, Newborn, and Child Health.

Indexed as

Child HealthMaternal DeathChildCost-Effectiveness AnalysisFemaleFinancing, GovernmentHealth ExpendituresHumansInfant, NewbornNigeriaPublic Policy

Identifiers

PMID36925179
PMCPMC10030457

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read9
measurements read107
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.